Daniel Porte Jr, 13 August 1931–13 May 2023 Steven E. KahnMichael W. Schwartz IN MEMORIAM 04 August 2023 Pages: 1759 - 1761
Incretins: turning the venom into the antidote Anna KrookHindrik Mulder Editorial 18 August 2023 Pages: 1762 - 1764
The expanding incretin universe: from basic biology to clinical translation Daniel J. DruckerJens J. Holst Review 28 March 2023 Pages: 1765 - 1779
Incretin hormones and type 2 diabetes Michael A. NauckTimo D. MĂĽller Review Open access 11 July 2023 Pages: 1780 - 1795
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy Matthias TschöpRuben NogueirasBo Ahrén Review Open access 20 May 2023 Pages: 1796 - 1808
Incretins beyond type 2 diabetes Chantal MathieuIraj Ahmadzai Review 08 August 2023 Pages: 1809 - 1819
Incretins and cardiovascular disease: to the heart of type 2 diabetes? Anna SoliniDomenico TricòStefano Del Prato Review Open access 05 August 2023 Pages: 1820 - 1831
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy Jonathan GoldneyJack A. SargeantMelanie J. Davies Review Open access 19 August 2023 Pages: 1832 - 1845
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease Christine R. AndreasenAndreas AndersenTina Vilsbøll Invited Review 27 July 2023 Pages: 1846 - 1858
Socioeconomic aspects of incretin-based therapy Thomas KaragiannisEleni BekiariApostolos Tsapas Review Open access 12 July 2023 Pages: 1859 - 1868
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study Matthew AnsonSizheng S. ZhaoUazman Alam Article Open access 28 July 2023 Pages: 1869 - 1881
Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial Anupam GarribSokoine Kivuyoon behalf of the META trial team Article Open access 18 July 2023 Pages: 1882 - 1896
Strength training is more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes: a randomised controlled trial Yukari KobayashiJin LongLatha Palaniappan Article 26 July 2023 Pages: 1897 - 1907
Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study Vanja KosjerinaBendix CarstensenDorte Vistisen Short Communication 28 July 2023 Pages: 1908 - 1913
Genetic associations vary across the spectrum of fasting serum insulin: results from the European IDEFICS/I.Family children’s cohort Kirsten MehligRonja Foraitaon behalf of the I.Family consortium Article Open access 07 July 2023 Pages: 1914 - 1924
Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production Yael RiahiAviram Kogot-LevinGil Leibowitz Extended Article 22 July 2023 Pages: 1925 - 1942
Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells Ruchi ShahTanya M. SpektorAlexander V. Ljubimov Article Open access 18 July 2023 Pages: 1943 - 1958